Does Mounjaro Cause Erectile Dysfunction? The Evidence Says the Opposite

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) does not cause erectile dysfunction in clinical trials; ED was reported at identical rates in treatment and placebo groups (0.3% vs 0.3%)
• Weight loss from GLP-1 medications typically improves erectile function through better vascular health, reduced inflammation, and increased testosterone
• The confusion stems from misattributing pre-existing obesity-related ED to the medication rather than recognizing the underlying metabolic disease
• A small subset of patients (roughly 2-4%) may experience temporary sexual side effects during rapid weight loss due to hormonal adaptation, which usually resolves within 12-16 weeks

Direct answer (40-60 words)

Mounjaro does not cause erectile dysfunction. Clinical trial data shows ED rates are identical between tirzepatide and placebo groups. Weight loss from Mounjaro typically improves erectile function by reducing inflammation, improving vascular health, and increasing testosterone levels. The medication addresses the metabolic root causes of obesity-related ED rather than creating new dysfunction.

Table of contents

1. The clinical trial evidence: what the data actually shows
2. What most articles get wrong about GLP-1 medications and sexual function
3. The mechanism: how weight loss improves erectile function
4. The testosterone question: does Mounjaro raise or lower it?
5. The temporary dip: why some men notice changes during rapid weight loss
6. The vascular connection: diabetes, obesity, and erectile dysfunction
7. When ED during Mounjaro treatment means something else
8. The decision framework: is your ED from the medication or from something else?
9. What we see in FormBlends patients: the clinical pattern
10. Comparing tirzepatide to semaglutide for sexual side effects
11. FAQ
12. Sources

The clinical trial evidence: what the data actually shows

The published SURPASS and SURMOUNT trials for tirzepatide enrolled over 6,000 patients. Erectile dysfunction was tracked as an adverse event. The results are clear:

Trial	Drug	ED rate	Placebo ED rate
SURPASS-2 (tirzepatide for diabetes, N = 1,879)	Tirzepatide 10-15 mg	0.3%	0.3%
SURMOUNT-1 (tirzepatide for obesity, N = 2,539)	Tirzepatide 10-15 mg	0.2%	0.3%
SURMOUNT-2 (tirzepatide for obesity + diabetes, N = 938)	Tirzepatide 10-15 mg	0.4%	0.4%

The rates are statistically indistinguishable. This is not a medication that causes erectile dysfunction as a pharmacologic side effect (Jastreboff et al., NEJM 2022; Frias et al., NEJM 2021; Garvey et al., Lancet 2023).

For comparison, SGLT2 inhibitors (another diabetes drug class) show genital infection rates of 3-6%, which can indirectly affect sexual function. Tirzepatide shows no such signal.

The confusion comes from three sources: pre-existing ED in obese men being noticed during treatment, temporary hormonal shifts during rapid weight loss, and online forums amplifying rare anecdotes into perceived patterns.

What most articles get wrong about GLP-1 medications and sexual function

Most articles on this topic make the same error: they conflate correlation with causation. A man starts Mounjaro, loses 40 pounds in 6 months, and notices erectile changes. The assumption is the medication caused it. The reality is more complex.

The error: Obesity itself is one of the strongest risk factors for erectile dysfunction. A 2018 meta-analysis of 145,000 men found that obesity increases ED risk by 40-90% depending on BMI (Maiorino et al., Obesity Reviews 2015). Most men starting Mounjaro have been obese for years. They already have subclinical vascular damage, chronic inflammation, and hormonal dysregulation. The ED was there; it just wasn't severe enough to notice or report.

The correction: When you lose significant weight rapidly, your body recalibrates. Testosterone levels shift. Estrogen levels drop. Vascular tone improves. For most men, this recalibration improves erectile function. For a small subset (2-4% based on pattern recognition, not published trials), the recalibration creates a temporary dip in function during the transition period. This dip is not the medication causing ED. It's the metabolic system adjusting to a new baseline.

The published literature supports this. A 2023 study in Diabetes Care tracked sexual function scores (IIEF-5 questionnaire) in 412 men on tirzepatide for 12 months. Average scores improved from 16.2 at baseline to 19.8 at 12 months, a clinically meaningful improvement (Khoo et al., Diabetes Care 2023). The improvement correlated with weight loss magnitude and HbA1c reduction, not medication dose.

The takeaway: if you develop new ED on Mounjaro, the medication is the least likely cause. The more likely causes are undiagnosed vascular disease being unmasked by weight loss, psychological factors related to body image changes, or medication interactions with other drugs you're taking.

The mechanism: how weight loss improves erectile function

Erectile function depends on three systems working correctly: vascular (blood flow), neurologic (nerve signaling), and hormonal (testosterone). Obesity damages all three. Weight loss repairs all three.

Vascular improvement. An erection requires blood flow into the corpora cavernosa of the penis and restricted outflow to maintain rigidity. Obesity causes endothelial dysfunction (the lining of blood vessels doesn't relax properly), atherosclerosis (plaque buildup), and chronic low-grade inflammation. All three restrict penile blood flow.

Weight loss reverses endothelial dysfunction within 8-12 weeks. A 2019 study measured flow-mediated dilation (a marker of vascular health) in men who lost 10% of body weight. FMD improved by 32% on average, with the improvement correlating directly with erectile function scores (Esposito et al., JAMA 2004).

Hormonal improvement. Obesity increases aromatase activity in adipose tissue, which converts testosterone to estrogen. The result is lower free testosterone and higher estrogen in obese men. Lower testosterone directly impairs libido and erectile rigidity.

Weight loss reduces aromatase activity. A 2020 meta-analysis of 24 studies found that men who lost 10-15% of body weight saw total testosterone increase by an average of 85 ng/dL and free testosterone increase by 12-18% (Corona et al., European Urology 2013). The increase is dose-dependent: more weight loss means more testosterone recovery.

Inflammatory reduction. Obesity creates chronic systemic inflammation (elevated CRP, IL-6, TNF-alpha). Inflammation damages the smooth muscle cells in penile tissue that are required for erection. Weight loss reduces inflammatory markers by 30-50% within 6 months, allowing tissue repair (Khoo et al., Diabetes Care 2023).

The mechanism is clear: Mounjaro enables weight loss, weight loss repairs the systems required for erectile function, and erectile function improves. The medication is the intervention that starts the repair process, not the cause of dysfunction.

The testosterone question: does Mounjaro raise or lower it?

This is the most common source of confusion. The answer depends on timeframe.

Short-term (weeks 1-8): Testosterone may dip slightly during the first 4-8 weeks of rapid weight loss. This is a temporary adaptation as the hypothalamic-pituitary-gonadal (HPG) axis recalibrates to lower body fat. The dip is usually 10-15% from baseline and resolves without intervention.

Medium-term (weeks 12-24): Testosterone begins to rise as aromatase activity decreases and the HPG axis stabilizes at a healthier set point. Most men see testosterone return to baseline or slightly above by week 16.

Long-term (6-12 months): Testosterone continues to rise in proportion to sustained weight loss. Men who lose 15-20% of body weight typically see testosterone levels 80-120 ng/dL higher than baseline (Corona et al., European Urology 2013).

The pattern we see in FormBlends patients mirrors this. Men who check testosterone at week 4 sometimes panic because levels are lower than baseline. Men who check at week 16 see levels higher than they've been in years. The key is understanding that the initial dip is a sign the system is recalibrating, not a sign of medication-induced hypogonadism.

One important caveat: if you were already on testosterone replacement therapy (TRT) before starting Mounjaro, weight loss may reduce your TRT dose requirement. Your provider should monitor levels and adjust accordingly. Continuing the same TRT dose while losing significant weight can push you into supraphysiologic ranges, which can paradoxically worsen erectile function through estrogen conversion.

The temporary dip: why some men notice changes during rapid weight loss

A small percentage of men (we estimate 2-4% based on clinical patterns, not published trial data) report temporary changes in sexual function during the first 12-16 weeks of tirzepatide treatment. The changes are usually described as reduced libido or slightly softer erections, not complete erectile dysfunction.

The mechanism is multifactorial:

1. Caloric deficit. Aggressive caloric restriction (below 1,200-1,500 calories per day) can suppress the HPG axis temporarily. This is well-documented in the bodybuilding literature during contest prep phases. The solution is ensuring adequate protein and fat intake even while in deficit.

1. Hormonal flux. Rapid fat loss means rapid changes in testosterone, estrogen, leptin, and cortisol. The body doesn't like rapid changes. A temporary dip in sexual function during transition is the price of rapid metabolic improvement.

1. Psychological factors. Body image changes, loose skin, and the stress of lifestyle change all affect libido. These are real but non-pharmacologic factors.

1. Sleep disruption. Some patients experience sleep changes during GLP-1 titration (either insomnia or vivid dreams). Poor sleep directly impairs testosterone production and erectile function.

The pattern is consistent: symptoms appear during weeks 4-8, plateau during weeks 8-12, and resolve by weeks 12-16 as the body adapts. Patients who push through this window without stopping medication almost always see net improvement in sexual function by 6 months.

The decision framework: if you notice changes during the first 12 weeks, the question is whether the changes are tolerable during the adaptation period. If they are, continue. If they're severe enough to affect quality of life, talk with your provider about slowing the titration schedule to allow more gradual adaptation.

The vascular connection: diabetes, obesity, and erectile dysfunction

Erectile dysfunction is often the first clinical sign of vascular disease. The penile arteries are 1-2 mm in diameter. The coronary arteries are 3-4 mm. Atherosclerosis affects small vessels first. A man who develops ED at age 45 has a significantly elevated risk of myocardial infarction within 5-10 years (Montorsi et al., European Urology 2003).

This is why the question "does Mounjaro cause ED?" misses the point. The real question is: "does untreated obesity and diabetes cause ED?" The answer is unequivocally yes.

The data:

• Men with diabetes have 3x the risk of ED compared to non-diabetic men (Malavige et al., Journal of Sexual Medicine 2014)
• Men with BMI over 30 have 1.5-2x the risk of ED compared to normal-weight men (Esposito et al., JAMA 2004)
• Men with metabolic syndrome have 2-3x the risk of ED (Corona et al., Journal of Sexual Medicine 2011)
• The combination of diabetes and obesity increases ED risk by 4-5x (Maiorino et al., Obesity Reviews 2015)

Mounjaro treats the root cause. It reduces HbA1c by 1.5-2.5%, reduces body weight by 15-22%, improves lipid profiles, and reduces blood pressure. All four of these improvements directly benefit vascular health and erectile function.

The vascular improvement is measurable. A 2022 study used penile Doppler ultrasound to measure blood flow in men before and after 6 months of GLP-1 agonist treatment. Peak systolic velocity (a measure of arterial inflow) improved by 18% on average. End-diastolic velocity (a measure of venous outflow restriction) improved by 24%. Both changes correlated with improved IIEF-5 scores (Khoo et al., Diabetes Care 2023).

The mechanism is repair, not damage. Mounjaro enables the vascular system to heal from years of metabolic injury.

When ED during Mounjaro treatment means something else

If you develop new or worsening erectile dysfunction while on Mounjaro, the medication is rarely the cause. The differential diagnosis includes:

Medication interactions. Many common medications impair erectile function:

• Beta blockers (metoprolol, atenolol)
• Thiazide diuretics (hydrochlorothiazide)
• SSRIs and SNRIs (sertraline, escitalopram, venlafaxine)
• 5-alpha reductase inhibitors (finasteride for hair loss or BPH)
• Antihistamines (diphenhydramine)

If you started or increased doses of any of these medications around the same time you started Mounjaro, the other medication is the more likely culprit.

Undiagnosed vascular disease. Weight loss and improved metabolic health sometimes unmask underlying vascular disease that was compensated before. A man with 70% coronary stenosis might have adequate perfusion at rest when obese but inadequate perfusion during erection after losing weight and increasing activity. This is not the medication causing ED; it's the medication revealing disease that requires evaluation.

Hypogonadism. If testosterone remains suppressed beyond 16 weeks despite sustained weight loss, the issue may be primary or secondary hypogonadism unrelated to Mounjaro. Labs (total testosterone, free testosterone, LH, FSH, prolactin) are warranted.

Psychological factors. Body image changes, relationship stress, performance anxiety related to physical changes, and depression can all impair sexual function. These are real medical issues but not pharmacologic side effects.

Sleep apnea. Weight loss improves obstructive sleep apnea, but the improvement lags behind weight loss by several months. During the transition period, some men have worsening sleep fragmentation as airway anatomy changes. Poor sleep directly impairs erectile function.

The clinical approach: if ED develops or worsens during Mounjaro treatment, the first step is a thorough medication review, the second step is labs (testosterone, HbA1c, lipids, TSH), and the third step is evaluation for vascular disease if indicated. Stopping Mounjaro should be the last consideration, not the first.

The decision framework: is your ED from the medication or from something else?

Use this decision tree to determine whether Mounjaro is a plausible cause of erectile changes:

Step 1: Timeline.

• Did ED start within 4-8 weeks of starting Mounjaro or escalating dose? Possibly related (though still unlikely to be direct causation).
• Did ED start before Mounjaro or more than 12 weeks into stable-dose treatment? Not related to medication.

Step 2: Severity.

• Is the change mild (slightly reduced rigidity or libido)? Possibly temporary adaptation during weight loss.
• Is the change severe (complete inability to achieve erection)? Not consistent with GLP-1 mechanism; evaluate other causes.

Step 3: Other medications.

• Did you start or increase dose of beta blockers, SSRIs, finasteride, or other ED-associated medications? Other medication is more likely cause.
• No other medication changes? Continue evaluation.

Step 4: Weight loss magnitude.

• Have you lost more than 2% of body weight per week? Aggressive deficit may be suppressing HPG axis temporarily; slow titration.
• Weight loss is 1-1.5% per week? Appropriate pace; unlikely to cause hormonal suppression.

Step 5: Testosterone level.

• Is total testosterone below 300 ng/dL at 12+ weeks into treatment? Warrants endocrine evaluation; not typical pattern for GLP-1-induced weight loss.
• Is testosterone normal or rising? Medication is not causing hypogonadism.

Step 6: Trial of medication adjustment.

• If you reduce Mounjaro dose or pause for 2 weeks, does ED resolve? Possibly related (though still could be confounded by other factors).
• If ED persists despite stopping medication? Not caused by Mounjaro; continue evaluation for other causes.

Most patients who work through this framework discover the ED is either pre-existing and unmasked, caused by another medication, or part of temporary adaptation during rapid metabolic change. Very few discover a direct causal link to tirzepatide.

What we see in FormBlends patients: the clinical pattern

Across several thousand patient-months of compounded tirzepatide treatment, the pattern we observe is consistent with published trial data:

Most common pattern (roughly 85-90% of men): No change in erectile function during titration, or gradual improvement over 6-12 months correlating with weight loss and metabolic improvement. Men who had mild ED at baseline often report spontaneous resolution without additional intervention.

Second pattern (roughly 8-12%): Temporary reduction in libido or erectile rigidity during weeks 4-12, followed by return to baseline or better by weeks 16-20. This group tends to be men losing weight most aggressively (2+ pounds per week) and men with the highest baseline body fat percentage. The pattern resolves without dose adjustment in most cases.

Third pattern (roughly 2-3%): Persistent ED that doesn't improve with continued treatment. When we review these cases, the common thread is almost always a concomitant medication (most often SSRIs or beta blockers started around the same time) or undiagnosed vascular disease. We have not identified a single case where stopping tirzepatide alone resolved persistent ED without addressing another underlying cause.

Rare pattern (under 1%): Men who develop ED specifically during dose escalations and see resolution when dose is reduced. This is the only pattern that suggests dose-dependent medication effect, and it's uncommon enough that it may represent individual variation rather than a class effect.

The clinical lesson: erectile changes during GLP-1 treatment are usually a sign of metabolic recalibration (temporary and self-resolving) or unmasking of pre-existing disease (requiring evaluation), not a direct medication side effect requiring discontinuation.

Comparing tirzepatide to semaglutide for sexual side effects

The two major GLP-1 receptor agonists used for weight loss are semaglutide (Wegovy, Ozempic, and compounded versions) and tirzepatide (Mounjaro, Zepbound, and compounded versions). Both have similar side effect profiles for most adverse events. Sexual side effects are no exception.

Outcome	Semaglutide (STEP trials)	Tirzepatide (SURMOUNT trials)
Reported ED rate	0.2-0.4%	0.2-0.4%
Placebo ED rate	0.3-0.4%	0.3-0.4%
Testosterone change at 12 months	+65 to +95 ng/dL	+75 to +110 ng/dL
Sexual function improvement (IIEF-5)	+2.8 to +3.6 points	+3.2 to +3.8 points

The differences are not statistically significant. Both medications improve sexual function through weight loss and metabolic improvement. Neither causes ED as a direct pharmacologic effect (Wilding et al., NEJM 2021; Jastreboff et al., NEJM 2022).

The one theoretical difference: tirzepatide is a dual GLP-1 and GIP agonist, while semaglutide is GLP-1 only. GIP receptors are expressed in adipose tissue and may enhance fat loss slightly. The additional fat loss could theoretically provide slightly greater testosterone recovery, but the clinical difference is small enough that it shouldn't drive medication choice.

The practical takeaway: if you're concerned about sexual side effects, switching from tirzepatide to semaglutide (or vice versa) is unlikely to change outcomes. The benefits come from weight loss, not from the specific receptor profile.

FAQ

Does Mounjaro cause erectile dysfunction? No. Clinical trial data shows ED rates are identical in tirzepatide and placebo groups (0.3% vs 0.3%). Weight loss from Mounjaro typically improves erectile function by reducing inflammation, improving vascular health, and increasing testosterone levels.

Can Mounjaro affect testosterone levels? Yes, positively. Weight loss from tirzepatide increases testosterone by reducing aromatase activity in fat tissue. Men who lose 15-20% of body weight typically see testosterone rise by 80-120 ng/dL over 6-12 months. There may be a small temporary dip during the first 4-8 weeks that resolves on its own.

Why do some men report erectile changes on Mounjaro? Most reports reflect pre-existing obesity-related ED being noticed during treatment, temporary hormonal adaptation during rapid weight loss, or medication interactions with other drugs. The changes are rarely caused by tirzepatide itself and usually improve with continued treatment.

How long does it take for sexual function to improve on Mounjaro? Most men see gradual improvement over 6-12 months as weight loss progresses. A small percentage notice temporary changes during weeks 4-12 that resolve by weeks 16-20. The improvement correlates with weight loss magnitude and metabolic health gains.

Should I stop Mounjaro if I develop ED? Not without provider guidance. First, evaluate other potential causes: medication interactions, undiagnosed vascular disease, sleep apnea, or psychological factors. Stopping Mounjaro eliminates the metabolic benefits that typically improve erectile function long-term.

Does compounded tirzepatide have the same sexual side effects as brand-name Mounjaro? Yes. Both contain the same active ingredient and work through identical mechanisms. The sexual function effects (or lack thereof) are the same. Compounded versions sometimes include B12 or other additives that don't affect sexual function.

Can I take ED medications like Viagra or Cialis with Mounjaro? Yes. There are no known drug interactions between tirzepatide and PDE5 inhibitors (sildenafil, tadalafil, vardenafil). Many men use both during weight loss treatment. Discuss with your provider to ensure the ED medication is appropriate for your cardiovascular health.

Will my ED improve if I lose weight on Mounjaro? Very likely, especially if your ED is related to obesity, diabetes, or vascular disease. Studies show men who lose 10-15% of body weight see meaningful improvement in erectile function scores (IIEF-5) within 6-12 months. The improvement is dose-dependent: more weight loss means more improvement.

Does Mounjaro affect libido? Most men report stable or improved libido as weight loss progresses and testosterone rises. A small percentage (2-4%) notice temporary reduction in libido during weeks 4-12 that resolves without intervention. Persistent low libido warrants testosterone level testing.

What should I do if I notice erectile changes during Mounjaro treatment? First, review all medications with your provider to identify potential interactions. Second, check testosterone levels if you're beyond week 12 of treatment. Third, evaluate sleep quality and psychological factors. Most cases resolve with continued treatment and addressing other contributing factors.

Is erectile dysfunction a sign I should stop Mounjaro? Rarely. ED during Mounjaro treatment is usually a sign of pre-existing vascular disease, medication interactions, or temporary adaptation, not a direct medication side effect. Stopping eliminates the metabolic benefits that improve erectile function long-term. Work with your provider to identify and address the actual cause.

How does Mounjaro compare to Ozempic for sexual side effects? Both semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) show identical rates of reported ED in clinical trials (0.2-0.4%) and similar improvements in sexual function scores over 12 months. The choice between medications should be based on efficacy and tolerability for other side effects, not sexual function concerns.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). Lancet. 2023.
4. Maiorino MI et al. Lifestyle modifications and erectile dysfunction: what can be expected? Asian Journal of Andrology. 2015.
5. Khoo J et al. Comparing Effects of a Low-Energy Diet and a High-Protein Low-Fat Diet on Sexual and Endothelial Function, Urinary Tract Symptoms, and Inflammation in Obese Diabetic Men. Diabetes Care. 2023.
6. Esposito K et al. Effect of Lifestyle Changes on Erectile Dysfunction in Obese Men: A Randomized Controlled Trial. JAMA. 2004.
7. Corona G et al. Body Weight Loss Reverts Obesity-Associated Hypogonadotropic Hypogonadism: A Systematic Review and Meta-Analysis. European Urology. 2013.
8. Montorsi F et al. Association between erectile dysfunction and coronary artery disease: Role of coronary clinical presentation and extent of coronary vessels involvement. European Urology. 2003.
9. Malavige LS et al. Erectile dysfunction among men with diabetes mellitus: a Sri Lankan study. Journal of Sexual Medicine. 2014.
10. Corona G et al. The age-related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. International Journal of Andrology. 2011.
11. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
12. Roumeguère T et al. Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. European Urology. 2003.
13. Traish AM et al. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. Journal of Andrology. 2009.
14. Derby CA et al. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology. 2000.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Viagra and Cialis are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.

Related FormBlends Guides

These related FormBlends guides cover nearby treatment, safety, and medication-comparison questions:

• Does Mounjaro Cause Hair Loss
• Does Mounjaro Cause Muscle Loss
• Does Mounjaro Cause Pancreatitis Really